Zytiga | malecare.org

ASCO 2014: Combining Advanced Hormone Therapies (Zytiga & Xtandi) Shows Promise for Men with Advanced Prostate Cancer

In my continuing reports about interesting and pertinent information released at the ASCO 2014 meeting one abstract described a phase 2 trial combining an attack on androgens in metastatic prostate cancer resistant to initial hormone therapy. This proof of concept study showed that combining Enzalutamide (Xtandi) plus abiraterone (Zytiga) drove down testosterone levels and appeared [...]

By Malecare|2017-10-19T10:48:10-04:00June 5th, 2014|2nd line hormone therapy, abiraterone acetate, ADT, Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, enzalutamide, Uncategorized, Xtandi, Zytiga|1 Comment

Does Prior Response to Zytiga Affect Subsequent Activity of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)?

Given all the newly approved drugs available to us to treat advanced prostate cancer there now are many questions about the optimal sequencing of these drugs and whether earlier use of one causes cross-resistance to another. Recently, it was reported that chemotherapy with docetaxel is inactive in men with metastatic castrate resistant prostate cancer (mCRPC) [...]

By Malecare|2017-10-19T10:48:19-04:00May 21st, 2014|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Cross Resistance, Drugs & Treatments, Research, Uncategorized, Understanding APC, Zytiga|0 Comments

NICE Rejects Zytiga for Men Without Chemotherapy Exposure

The National Institute for Health and Care Excellence (NICE), which is Britain’s healthcare cost-effectiveness agency, has determined that abiraterone (Zytiga) was not worth giving to men with castrate resistant metastatic prostate cancer who have yet to had chemotherapy. Unlike the FDA in the United States which rules only on a drug’s efficacy, NICE decides if [...]

By Malecare|2014-05-14T10:53:53-04:00May 14th, 2014|Advanced Prostate Cancer, General Information, NICE, Uncategorized, United Kingdom - England, Northern Ireland, Scotland & Wales, Zytiga|4 Comments

A Surprising Biochemical Response to Ketoconazole In Post-Chemotherapy mCRPC Men When Compared to the Zytiga Trial Results

It has always been assumed that Ketoconazole, when used for the treatment of men with metastatic castration resistant prostate cancer (mCRPC), would not be as potent as abiraterone (Zytiga), but there has never been any head to head comparison to demonstrate this assumption! Ketoconazole is a less potent inhibitor of the CYP-17 enzyme, the mode [...]

By Malecare|2014-05-12T17:10:17-04:00May 12th, 2014|2nd line hormone therapy, Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, ketoconazole, Uncategorized, Understanding APC, Zytiga|0 Comments

NICE Recommends Xtandi for Men with Prior Zytiga Exposure – Good News for our Brothers and Ammunition to Appeal Step Therapy

There is some really good news for those of us who live in areas where The National Institute for Health and Care Excellence (NICE) recommends drug approvals. NICE has issued a final draft guidance recommending that men with hormone-relapsed prostate cancer (castrate resistant) that has metastasized and has been treated with docetaxel (chemotherapy) should be [...]

By Malecare|2014-05-09T10:43:23-04:00May 9th, 2014|abiraterone acetate, Advanced Prostate Cancer, Drugs & Treatments, enzalutamide, step therapy, Uncategorized, United Kingdom - England, Northern Ireland, Scotland & Wales, Xtandi, Zytiga|0 Comments